Vitamin K Supplementation in Post-Menopausal Osteopenia
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether supplementation with 5 mg vitamin K daily over a 2-year period will prevent bone loss in post-menopausal women with osteopenia.
| Condition | Intervention | Phase |
|---|---|---|
|
Post-Menopausal Osteoporosis Post-Menopausal Osteopenia |
Dietary Supplement: vitamin K1 (phylloquinone) Dietary Supplement: placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial) |
- Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms. [ Time Frame: 0 to 24 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms. [ Time Frame: 0 to 24 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms. [ Time Frame: 0 to 24 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms. [ Time Frame: 0 to 24 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker [ Time Frame: 0-24 months ] [ Designated as safety issue: No ]measured by osteocalcin on elecsys platform
- Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX) [ Time Frame: 0-24 months ] [ Designated as safety issue: No ]measured by CTX Elisa assay on elecsys platform
- Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin [ Time Frame: 0 to 24 months ] [ Designated as safety issue: No ]measured by osteocalcin hydroxyapatite binding assay
- Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms. [ Time Frame: 0 to 48 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms. [ Time Frame: 0 to 48 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms. [ Time Frame: 0 to 48 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms. [ Time Frame: 0 to 48 months ] [ Designated as safety issue: No ]BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer
- Difference in Serious Adverse Events [ Time Frame: up to 48 months ] [ Designated as safety issue: Yes ]These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death.
- Difference in Number of New Cancers by Treatment Arm. [ Time Frame: up to 48 months ] [ Designated as safety issue: Yes ]
- Difference in Number of New Clinical Fractures by Treatment Arm. [ Time Frame: up to 48 months ] [ Designated as safety issue: Yes ]these included fragility fractures
| Enrollment: | 440 |
| Study Start Date: | January 2002 |
| Study Completion Date: | September 2007 |
| Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: phyloquinone
5 mg Vitamin K1
|
Dietary Supplement: vitamin K1 (phylloquinone) |
| Placebo Comparator: placebo |
Dietary Supplement: placebo
1 pill daily
|
Detailed Description:
Osteoporosis is major cause of morbidity and mortality in Canadian postmenopausal women. It is a systemic disease characterized by low bone mass and deterioration of bone microarchitecture, resulting in bone fragility and an increased risk of fractures. One in six women over the age of 50 have osteoporosis. The lifetime risk of an osteoporotic fracture for an average 50 year-old Canadian woman is >40%. The annual health care costs for osteoporotic fractures in Canada have been estimated to exceed $1.3 billion.
Recent data suggest that vitamin K supplements may decrease bone loss and prevent fractures. Vitamin K is a co-factor of gamma-glutamyl carboxylase, an enzyme that catalyzes the gamma-carboxylation of glutamic acid residues in bone matrix proteins such as osteocalcin. Vitamin K has been reported to enhance bone formation in both in vitro studies and in vivo studies in animals. Vitamin K levels are low in individuals with osteoporosis and in patients with osteoporotic fractures. The few studies examining vitamin K supplementation in humans have showed promising results with no significant side effects, but these studies had significant methodological shortcomings such as inadequate sample size and lack of randomization.
The primary objective of our study is to examine whether vitamin K supplementation will increase bone mineral density in postmenopausal women with osteopenia. Our secondary objectives are to examine the possible adverse effects from long-term vitamin K supplementation, to investigate whether vitamin K will decrease risk of fractures and to determine if vitamin K affects quality of life. Our hypotheses are that vitamin K increases bone mineral density in postmenopausal women, and that there are no significant adverse effects from vitamin K supplementation.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Postmenopausal: One year since the natural cessation of menses, or Hysterectomy with either postmenopausal status confirmed by FSH lab values, or age 55 and above AND 2. Osteopenic: T-score at baseline has to be between (and including) -1.0 and
-2.0 in the lumbar spine (L1-L4), total hip or femoral neck, and the lowest reading of the above three measurements must be between -1.0 and -2.0
Exclusion Criteria:
- Women ever having had a fragility fracture after age 40;
- Women currently on anticoagulants, previously on anticoagulants in the past 3 months, or expected to be on anticoagulants in the near future;
- Women on hormone replacement therapy, raloxifene, bisphosphonates or calcitonin during the past 3 months;
- Women who have ever been on a bisphosphonate for more than 6 months;
- Women previously diagnosed with Paget's disease, hyperparathyroidism, hyperthyroidism or other metabolic bone diseases;
- Women with decompensated diseases of the liver, kidney, pancreas, lung, or heart;
- Women with a history of active cancer in the past 5 years;
- Women taking mega-doses of vitamin A (more than 10,000 iu per day) or E (more than 400 iu per day);
- Women involved in other clinical trials;
- Any women who, in the opinion of the principal investigator, is at poor medical or psychiatric risk for the study.
Contacts and Locations| Canada, Ontario | |
| University Health Network, Osteoporosis Department | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| St. Michael's Hospital Health Centre | |
| Toronto, Ontario, Canada, M5C 2T2 | |
| Sunnybrook & Women's College Health Sciences Centre | |
| Toronto, Ontario, Canada, M5S 1B2 | |
| Mt. Sinai Hospital | |
| Toronto, Ontario, Canada, M5G 1X5 | |
| University of Toronto | |
| Toronto, Ontario, Canada, M5S 3E2 | |
| Principal Investigator: | Angela M Cheung, MD, PhD | University Health Network, University of Toronto |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00150969 History of Changes |
| Other Study ID Numbers: | CIHR-50422 |
| Study First Received: | September 6, 2005 |
| Results First Received: | January 10, 2012 |
| Last Updated: | February 23, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University Health Network, Toronto:
|
vitamin K bone mineral density post-menopausal women |
randomized double blind placebo controlled trial osteoporosis women's health |
Additional relevant MeSH terms:
|
Bone Diseases, Metabolic Osteoporosis Osteoporosis, Postmenopausal Bone Diseases Musculoskeletal Diseases Vitamin K 1 Vitamin K Vitamins Micronutrients Growth Substances |
Physiological Effects of Drugs Pharmacologic Actions Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 16, 2012
